Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.94
BIO.B's Cash-to-Debt is ranked lower than
55% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. BIO.B: 1.94 )
Ranked among companies with meaningful Cash-to-Debt only.
BIO.B' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.03  Med: 0.45 Max: 1.94
Current: 1.94
0.03
1.94
Equity-to-Asset 0.67
BIO.B's Equity-to-Asset is ranked higher than
64% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. BIO.B: 0.67 )
Ranked among companies with meaningful Equity-to-Asset only.
BIO.B' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.5 Max: 0.67
Current: 0.67
0.33
0.67
Interest Coverage 2.42
BIO.B's Interest Coverage is ranked lower than
91% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 80.49 vs. BIO.B: 2.42 )
Ranked among companies with meaningful Interest Coverage only.
BIO.B' s Interest Coverage Range Over the Past 10 Years
Min: 2.42  Med: 5.04 Max: 7.69
Current: 2.42
2.42
7.69
Piotroski F-Score: 4
Altman Z-Score: 4.49
Beneish M-Score: -2.77
WACC vs ROIC
7.28%
1.65%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % 2.57
BIO.B's Operating Margin % is ranked lower than
51% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. BIO.B: 2.57 )
Ranked among companies with meaningful Operating Margin % only.
BIO.B' s Operating Margin % Range Over the Past 10 Years
Min: 2.57  Med: 9.81 Max: 14.74
Current: 2.57
2.57
14.74
Net Margin % 1.36
BIO.B's Net Margin % is ranked higher than
52% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. BIO.B: 1.36 )
Ranked among companies with meaningful Net Margin % only.
BIO.B' s Net Margin % Range Over the Past 10 Years
Min: 1.36  Med: 5.98 Max: 9.63
Current: 1.36
1.36
9.63
ROE % 1.09
BIO.B's ROE % is ranked higher than
51% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. BIO.B: 1.09 )
Ranked among companies with meaningful ROE % only.
BIO.B' s ROE % Range Over the Past 10 Years
Min: 1.09  Med: 8.85 Max: 13.27
Current: 1.09
1.09
13.27
ROA % 0.73
BIO.B's ROA % is ranked higher than
55% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. BIO.B: 0.73 )
Ranked among companies with meaningful ROA % only.
BIO.B' s ROA % Range Over the Past 10 Years
Min: 0.73  Med: 4.77 Max: 6.63
Current: 0.73
0.73
6.63
ROC (Joel Greenblatt) % 6.10
BIO.B's ROC (Joel Greenblatt) % is ranked higher than
54% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. BIO.B: 6.10 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BIO.B' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 6.1  Med: 25.09 Max: 36.51
Current: 6.1
6.1
36.51
3-Year Revenue Growth Rate -1.80
BIO.B's 3-Year Revenue Growth Rate is ranked lower than
68% of the 147 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. BIO.B: -1.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BIO.B' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -1.8  Med: 8.3 Max: 21
Current: -1.8
-1.8
21
3-Year EBITDA Growth Rate -14.40
BIO.B's 3-Year EBITDA Growth Rate is ranked lower than
72% of the 137 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.50 vs. BIO.B: -14.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BIO.B' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -14.4  Med: 8.4 Max: 40.2
Current: -14.4
-14.4
40.2
3-Year EPS without NRI Growth Rate -29.30
BIO.B's 3-Year EPS without NRI Growth Rate is ranked lower than
80% of the 124 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.70 vs. BIO.B: -29.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BIO.B' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -36.8  Med: 10.2 Max: 112
Current: -29.3
-36.8
112
GuruFocus has detected 5 Warning Signs with Bio-Rad Laboratories Inc $BIO.B.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BIO.B's 10-Y Financials

Financials (Next Earnings Date: 2017-05-04)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

BIO.B Guru Trades in

BIO.B Guru Trades in

BIO.B Guru Trades in

Q4 2016

BIO.B Guru Trades in Q4 2016

Jim Simons 1,100 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with BIO.B

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 334516    SIC: 3826
Compare:NYSE:PKI, NAS:QGEN, NAS:DXCM, OTCPK:ERFSF, NAS:ICLR, NYSE:CRL, NAS:PRAH, OTCPK:SWTUY, NAS:CPHD, NAS:BRKR, NAS:VWR, OTCPK:CZMWY, NYSE:ALR, OTCPK:DSRLF, NAS:PRXL, NAS:EXAS, NAS:NEOG, NAS:INCR, NAS:MYGN, NAS:AXDX » details
Traded in other countries:BUWA.Germany,
Headquarter Location:USA
Bio-Rad Laboratories Inc manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a products and systems used to separate complex chemical and biological materials.

Bio-Rad Laboratories Inc was founded in 1952 and incorporated in 1957. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates in two industry segments designated as Life Science and Clinical Diagnostics. Life science is the study of the characteristics, behavior, and structure of living organisms and their component systems. Life Science segment is at the forefront of discovery, creating tools to answer complex biological questions. The Company is engaged in developing, manufacturing and marketing a range of more than 5,000 reagents, apparatus and laboratory instruments that serve a wide customer base. Many of its products are used in established research techniques, biopharmaceutical production processes and food testing regimes. These techniques are typically used to separate, purify and identify biological materials such as proteins, nucleic acids and bacteria within a laboratory or production setting. Its main life science customers include universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers and food testing laboratories. Clinical Diagnostics segment designs, manufactures, sells and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the diagnostics market. Its products currently address specific niches within the in vitro diagnostics (IVD) test market. It supplies more than 3,000 different products that cover more than 300 clinical diagnostic tests to the IVD test market. IVD tests are conducted outside the human body and are used to identify and measure substances in a patient's tissue, blood or urine. Its products consist of reagents, instruments and software, typically provided to its customers as an integrated package to allow them to generate reproducible test results. Its main clinical diagnostic customers include hospital laboratories, reference laboratories, transfusion laboratories and physician office laboratories. The Company owns numerous U.S. and international patents and patent licenses. Each of the Company's segments maintains a sales force to sell its products on a direct basis. Major competitors in the clinical diagnostic segment include Roche, Abbott Laboratories (Diagnostic Division), Siemens Medical Diagnostics Solutions (formerly Dade-Behring, Diagnostics Products Corporation, and Bayer Diagnostics), Beckman Coulter, Becton-Dickinson, bioMérieux, Johnson & Johnson (Ortho Clinical Diagnostics), Thermo Fisher, Tosoh, Immucor, Cepheid, and DiaSorin. The Company's operations are subject to federal, state, local and foreign environmental laws and regulations that govern such activities as transportation of goods, emissio

Top Ranked Articles about Bio-Rad Laboratories Inc

Bio-Rad Unveils Amplichek II Quality Control, the First in a Series of Controls for the Molecular Diagnostics Testing Market

HERCULES, CA--(Marketwired - May 23, 2016) - Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B), a global provider of life science research and clinical diagnostic products, today announced its entry into the rapidly growing molecular diagnostics testing market with the launch of Amplichek™ II quality control, which was recently issued a de novo clearance from the U.S. Food and Drug Administration (FDA). The FDA's de novo clearance is a classification given to devices that are considered novel, with no existing classification or predicate device on the market. Amplichek II began shipping in May and is the first in a series of infectious disease controls that Bio-Rad plans to introduce for the molecular diagnostic testing market. Molecular diagnostics is one of the fastest growing IVD markets, estimated to reach $9.3 billion by 2020 with the infectious disease segment accounting for the largest share of the global market, according to a 2015 report by research firm MarketsandMarkets. "Our Amplichek II quality control complements our already extensive range of quality controls and reflects our commitment to offer innovative products that help improve laboratory analytical performance," said John Hertia, Bio-Rad President, Clinical Diagnostics Group. Amplichek II is an independent, multi-analyte quality control that monitors the performance of in vitro laboratory nucleic acid testing procedures for the qualitative detection of Healthcare Associated Infections (HAIs). HAIs can occur during the process of patient care within a healthcare facility. Millions of Healthcare Associated Infections occur each year, leading to significantly high mortality rates. According to the Centers for Disease Control and Prevention, on any given day, about one in 25 hospital patients have at least one Healthcare Associated Infection. Early detection of these pathogens combined with the appropriate infection control procedures can help prevent the spread of HAIs and lead to improved patient care. About Bio-Rad

Bio-Rad Laboratories, Inc. (NYSE: BIO) (NYSE: BIO.B) develops, manufactures, and markets a broad range of innovative products and solutions for the life science research and clinical diagnostic markets. The company is renowned for its commitment to quality and customer service among university and research institutions, hospitals, public health and commercial laboratories, as well as the biotechnology, pharmaceutical, and food safety industries. Founded in 1952, Bio-Rad is based in Hercules, California, and serves more than 100,000 research and healthcare industry customers through its global network of operations. The company employs more than 7,800 people worldwide and had revenues exceeding $2 billion in 2015. For more information, please visit www.bio-rad.com Bio-Rad Forward-Looking Statements

This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding plans to introduce products to the molecular diagnostics testing market and our development and launch of new products. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "plan", "believe," "expect," "anticipate," "may," "will," "intend," "estimate," "continue," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include our ability to develop and market new or improved products, our ability to compete effectively, international legal and regulatory risks, and product quality and liability issues. For further information regarding our risks and uncertainties, please refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" in Bio-Rad's public reports filed with the Securities and Exchange Commission, including our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and our Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2016. Bio-Rad cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. We disclaim any obligation to update these forward-looking statements.


Press Contact:

Bio-Rad Laboratories, Inc.

Tina Cuccia

Corporate Communications

510-724-7000

Email Contact





Read more...

Ratios

vs
industry
vs
history
PE Ratio 222.73
BIO.B's PE Ratio is ranked lower than
98% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 30.62 vs. BIO.B: 222.73 )
Ranked among companies with meaningful PE Ratio only.
BIO.B' s PE Ratio Range Over the Past 10 Years
Min: 13.66  Med: 22.9 Max: 222.73
Current: 222.73
13.66
222.73
Forward PE Ratio 59.52
BIO.B's Forward PE Ratio is ranked lower than
91% of the 81 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.79 vs. BIO.B: 59.52 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 222.73
BIO.B's PE Ratio without NRI is ranked lower than
98% of the 104 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 31.50 vs. BIO.B: 222.73 )
Ranked among companies with meaningful PE Ratio without NRI only.
BIO.B' s PE Ratio without NRI Range Over the Past 10 Years
Min: 13.66  Med: 22.9 Max: 222.73
Current: 222.73
13.66
222.73
Price-to-Owner-Earnings 252.49
BIO.B's Price-to-Owner-Earnings is ranked lower than
95% of the 64 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.82 vs. BIO.B: 252.49 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BIO.B' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 9.69  Med: 20.11 Max: 252.49
Current: 252.49
9.69
252.49
PB Ratio 2.42
BIO.B's PB Ratio is ranked higher than
72% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. BIO.B: 2.42 )
Ranked among companies with meaningful PB Ratio only.
BIO.B' s PB Ratio Range Over the Past 10 Years
Min: 1.45  Med: 1.8 Max: 3.02
Current: 2.42
1.45
3.02
PS Ratio 3.03
BIO.B's PS Ratio is ranked higher than
57% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. BIO.B: 3.03 )
Ranked among companies with meaningful PS Ratio only.
BIO.B' s PS Ratio Range Over the Past 10 Years
Min: 0.87  Med: 1.58 Max: 3.03
Current: 3.03
0.87
3.03
Price-to-Free-Cash-Flow 83.93
BIO.B's Price-to-Free-Cash-Flow is ranked lower than
85% of the 71 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.50 vs. BIO.B: 83.93 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BIO.B' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 9.61  Med: 25.53 Max: 155.5
Current: 83.93
9.61
155.5
Price-to-Operating-Cash-Flow 28.97
BIO.B's Price-to-Operating-Cash-Flow is ranked lower than
66% of the 86 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.60 vs. BIO.B: 28.97 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BIO.B' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 7.48  Med: 13.03 Max: 32.49
Current: 28.97
7.48
32.49
EV-to-EBIT 86.41
BIO.B's EV-to-EBIT is ranked lower than
94% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. BIO.B: 86.41 )
Ranked among companies with meaningful EV-to-EBIT only.
BIO.B' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.4  Med: 13.5 Max: 92.3
Current: 86.41
8.4
92.3
EV-to-EBITDA 26.58
BIO.B's EV-to-EBITDA is ranked lower than
76% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. BIO.B: 26.58 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIO.B' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6  Med: 9.3 Max: 28.4
Current: 26.58
6
28.4
Shiller PE Ratio 47.32
BIO.B's Shiller PE Ratio is ranked lower than
63% of the 30 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 39.15 vs. BIO.B: 47.32 )
Ranked among companies with meaningful Shiller PE Ratio only.
BIO.B' s Shiller PE Ratio Range Over the Past 10 Years
Min: 19.56  Med: 28.68 Max: 47.34
Current: 47.32
19.56
47.34
Current Ratio 3.91
BIO.B's Current Ratio is ranked higher than
66% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. BIO.B: 3.91 )
Ranked among companies with meaningful Current Ratio only.
BIO.B' s Current Ratio Range Over the Past 10 Years
Min: 1.67  Med: 2.45 Max: 4.1
Current: 3.91
1.67
4.1
Quick Ratio 2.80
BIO.B's Quick Ratio is ranked higher than
61% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. BIO.B: 2.80 )
Ranked among companies with meaningful Quick Ratio only.
BIO.B' s Quick Ratio Range Over the Past 10 Years
Min: 0.95  Med: 1.55 Max: 3.14
Current: 2.8
0.95
3.14
Days Inventory 207.71
BIO.B's Days Inventory is ranked lower than
89% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. BIO.B: 207.71 )
Ranked among companies with meaningful Days Inventory only.
BIO.B' s Days Inventory Range Over the Past 10 Years
Min: 156.44  Med: 173.53 Max: 207.71
Current: 207.71
156.44
207.71
Days Sales Outstanding 65.71
BIO.B's Days Sales Outstanding is ranked lower than
55% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. BIO.B: 65.71 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIO.B' s Days Sales Outstanding Range Over the Past 10 Years
Min: 63.37  Med: 70.54 Max: 89.45
Current: 65.71
63.37
89.45
Days Payable 52.24
BIO.B's Days Payable is ranked lower than
52% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. BIO.B: 52.24 )
Ranked among companies with meaningful Days Payable only.
BIO.B' s Days Payable Range Over the Past 10 Years
Min: 43.27  Med: 52.25 Max: 56.81
Current: 52.24
43.27
56.81

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -0.90
BIO.B's 3-Year Average Share Buyback Ratio is ranked higher than
74% of the 139 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.00 vs. BIO.B: -0.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIO.B' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.6  Med: -1 Max: -0.2
Current: -0.9
-1.6
-0.2

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 10.76
BIO.B's Price-to-Net-Current-Asset-Value is ranked lower than
57% of the 122 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.79 vs. BIO.B: 10.76 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
BIO.B' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.17  Med: 7.17 Max: 95.94
Current: 10.76
3.17
95.94
Price-to-Tangible-Book 3.21
BIO.B's Price-to-Tangible-Book is ranked higher than
72% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.28 vs. BIO.B: 3.21 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BIO.B' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.74  Med: 2.54 Max: 6.43
Current: 3.21
0.74
6.43
Price-to-Intrinsic-Value-Projected-FCF 2.05
BIO.B's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
51% of the 70 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.10 vs. BIO.B: 2.05 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BIO.B' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.81  Med: 1.54 Max: 20.39
Current: 2.05
0.81
20.39
Price-to-Median-PS-Value 1.92
BIO.B's Price-to-Median-PS-Value is ranked lower than
87% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. BIO.B: 1.92 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BIO.B' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.14  Med: 0.75 Max: 1.92
Current: 1.92
0.14
1.92
Price-to-Graham-Number 5.64
BIO.B's Price-to-Graham-Number is ranked lower than
84% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.97 vs. BIO.B: 5.64 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BIO.B' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.7  Med: 1.45 Max: 5.64
Current: 5.64
0.7
5.64
Earnings Yield (Greenblatt) % 1.16
BIO.B's Earnings Yield (Greenblatt) % is ranked lower than
56% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. BIO.B: 1.16 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BIO.B' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.1  Med: 7.4 Max: 11.9
Current: 1.16
1.1
11.9
Forward Rate of Return (Yacktman) % -9.25
BIO.B's Forward Rate of Return (Yacktman) % is ranked lower than
88% of the 59 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 8.75 vs. BIO.B: -9.25 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BIO.B' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -9.25  Med: 10.4 Max: 22.4
Current: -9.25
-9.25
22.4

More Statistics

Revenue (TTM) (Mil) $2,068
EPS (TTM) $ 0.95
Beta0.76
Short Percentage of Float0.29%
52-Week Range $136.27 - 210.50
Shares Outstanding (Mil)29.58

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 2,125 2,218 2,315
EPS ($) 3.50 4.29 5.24
EPS without NRI ($) 3.50 4.29 5.24
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for BIO.B

Headlines

Articles On GuruFocus.com
Maxcom Telecomunicaciones Announces Tender Offer For Step-up Senior Notes Due 2020 Apr 25 2017 
/C O R R E C T I O N -- Alaska Airlines/ Apr 25 2017 
JBS SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against JBS S.A. Apr 25 2017 
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against The Apr 25 2017 
BB&T declares second-quarter dividends Apr 25 2017 
ONE WEEK DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Babcock & Wilcox Apr 25 2017 
Sears Hometown Store in Rochester Refreshes into “America’s Appliance Experts” Model Apr 25 2017 
Sears Hometown Store in Rutland Simplifies Appliance Shopping Experience with Store Refresh Apr 25 2017 
Sears Appliance & Hardware in Cedar City Transforms into “America’s Appliance Experts® Apr 25 2017 
Sears Hometown Store in Livingston Refreshes Appliance Shopping Experience Apr 25 2017 

More From Other Websites
Bio-Rad to Report First-Quarter 2017 Financial Results Thursday, May 4, 2017 Apr 10 2017
Bio-Rad Intends to Propose Three New Independent Directors Mar 13 2017
Bio-Rad Initiates Long Term Financial Guidance; Commits to Defining Long Term Capital Allocation... Mar 13 2017
Bio-Rad Laboratories, Inc. :BIO.B-US: Earnings Analysis: Q4, 2016 By the Numbers : February 27, 2017 Feb 27 2017
Bio-Rad Reports 4Q Loss, Flat Revenue Feb 27 2017
Bio-Rad reports 4Q loss Feb 24 2017
Bio-Rad Reports Fourth-Quarter and Full-Year 2016 Financial Results Feb 23 2017
Bio-Rad to Report Fourth-Quarter and Full-Year 2016 Financial Results Thursday, February 23, 2017 Jan 18 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bio-Rad... Jan 18 2017
Bio-Rad to Acquire RainDance Technologies and Droplet Intellectual Property Jan 16 2017
Illumina and Bio-Rad Unveil Single-Cell Sequencing Solution Jan 12 2017
Stocks Mixed; Why Are Illumina, Valeant, Barracuda Soaring? Jan 10 2017
Illumina and Bio-Rad Launch Solution for Single-Cell Genomic Sequencing to Enable Robust Study of... Jan 09 2017
Hedge Funds Are Betting On Bio-Rad Laboratories, Inc. (BIO) Dec 01 2016
Medical Product Nov 1 Earnings Lineup: CERN, IDXX, DXCM, BIO Oct 31 2016
Bio-Rad Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : BIO.B-US :... Oct 27 2016
ETF’s with exposure to Bio-Rad Laboratories, Inc. : October 13, 2016 Oct 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)